Fiona Marshall on structure-based GPCR drug discovery, the GABA-B heterodimer, the acetate that rewrote design as a productive strategy across GPCR families. Scientific Themes of the Conversation Structure-based GPCR drug design and the thermostabilization breakthrough drug design 18:47 Which GPCR families pharma is chasing now — and why 21:23 Why animal model validation stabilization and structure-based drug design.

Brian Arey on GPCR drug discovery from the inside - GPR56 mechanotransduction, the KLF2 pathway, organizational Drug Discovery and the Science Nobody Publishes Drug discovery in the pharmaceutical industry generates The "killer experiment" is the one designed to end your own program A mentor taught Arey the concept He continues to pioneer in drug discovery studying GPCRs and other target classes. GPCR Podcast? Leave a Review.

classes of drug targets in modern pharmacology. molecular structures inform the design and development of new therapeutics. in membrane protein research GPCR pharmacology and drug discovery strategies Opioid receptor structure GPCR Drug Discovery Is Increasingly Structural Modern GPCR drug discovery increasingly integrates structural I would like to remain in drug discovery , ideally working on GPCRs if possible.

Explore Martin Marro’s impact on GPCR drug discovery, assay innovation, and translational pharmacology , Bias, and Translational Drug Discovery Scientific Abstract A recurring problem in GPCR drug discovery bar for what counts as true biased agonism - Receptor trafficking, internalization, and recycling as design GPCRs at Tectonic - 51:03 From green to red: transgenic wheat to GPCR drug discovery - 54:26 Advice Most drugs won't make it.

Masha Niv on bitter taste GPCRs, the drug bitterness blind spot, and what heavy water reveals about the architecture and pharmacological consequences 41:58 - Taste GPCRs as drug targets - asthma, cardiac GPCR Ecosystem Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

Five scientists audit what AI can and can't do for GPCR drug discovery — from orphan receptors and biased Drug Discovery? drug discovery, or is it mostly a rebranding of methods the field has used for decades? from known peptides Generative models, scoring functions, and the role of molecular dynamics in ligand design GPCR-targeting drugs represent roughly 0.9 trillion dollars in global sales across 75 countries.

Eurofins Discovery: Comprehensive GPCR Solutions for Confident Drug Discovery Your One-Stop-Shop for End-to-End GPCR Drug Discovery Services Explore capabilities Start a conversation As a trusted discovery Backed by more than 30 years of GPCR experience, including 20+ years of successful Integrated Drug Discovery View Integrated Drug Discovery End-to-end programs from target validation through candidate advancement , the peptide hormone receptors central to metabolic and endocrine drug discovery Recently launched GSIS

GPCR unites researchers, industry, and partners to accelerate GPCR science and drug discovery—through GPCR Ecosystem We unite the GPCR community to advance drug discovery. We bring the GPCR community together to fuel GPCR drug discovery—one receptor at a time. Contact Us Our Mission Advance GPCR science and drug discovery by connecting people, data, and opportunities across the global GPCR ecosystem.

Topics Covered The biological basis of receptor signaling bias and ligand-dependent conformations How to design Every session is designed to move your science forward. First Dr. GPCR event? Welcome. They're designed for scientists who want deep, data-driven discussion rather than surface-level overviews These sessions are designed for interaction — scientists asking direct questions and getting real answers GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design

GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery virtual drug screening to identify agonists and antagonists targeting Class A GPCRs.

GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the on GPCRs. biology and for the identification of drug targets and future drug development.

GPCR signaling in disease. << Back to podcast list Strategic Partner(s) Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar In this episode, host Dr. Ilana Kotliar , his former graduate student, to explore the development of powerful multiplex tools designed About Tom Sakmar Tom Sakmar is a physician-scientist and Rockefeller University professor dedicated to drug He and his artist/designer wife, Karina Åberg, have three teenage children.

These webinars are designed for scientists who want deep, data-driven discussion rather than surface-level discovery If you work directly with receptor systems, ligand design, efficacy modeling, or signaling These webinars are designed for scientists with foundational knowledge in receptor pharmacology, signaling These webinars are designed to support ongoing scientific development in GPCR pharmacology and drug discovery These programs are designed for scientists seeking advanced, mechanism-focused training in GPCR biology

Design and Pharmacology, with a part-time affiliation at the Institute for Biological Psychiatry. This has direct implications for how drug safety is assessed and how clinical trials are designed. 2. , Hauser designed a ligand library by learning the structural and evolutionary logic of known peptide The patient impact requires the clinician's voice in the design phase. 6. During his Ph.D. with David Gloriam at the Department of Drug Design and Pharmacology in Copenhagen,

Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, GPCR Foundry: Accelerate GPCR Drug Discovery Move from idea to insight—faster, smarter, and with confidence Get Team Access GPCR University Expert-led courses spanning GPCR drug discovery — from receptor biology GPCR ecosystem. biotech innovators and showcase your expertise Training & Upskilling Specialized, insight-packed courses designed

Terry Kenakin on tuning GPCR system sensitivity to reveal true drug activity. September 24, 2026. Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development GPCR Dr. GPCR is a membership-based nonprofit ecosystem dedicated to advancing GPCR-targeted drug discovery. Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics These industry-standard assays, designed for regulatory submissions, are backed by partnerships with , Eurofins DiscoverX provides you with a variety of drug discovery and development products with multiple research and drug discovery and development. GPCR services, the benefits from integration provide the most comprehensive GPCR research and drug discovery

GPCR University. Aside from his vast experience in drug development, not to mention his extensive publication record, biology, or drug discovery. The Masterclass is designed for GPCR researchers, pharmacologists, and drug discovery scientists working Experts explain how they think about pharmacological data, experimental design, and discovery challenges—insight

Terry Kenakin on detecting, quantifying, and applying receptor signaling bias in GPCR drug discovery. Candidates Turning functional selectivity into a practical decision-making tool in GPCR drug discovery Organizers Eurofins DiscoverX Eurofins DiscoverX is a one-stop-shop for GPCR drug discovery and development GPCR is a membership-based nonprofit ecosystem dedicated to advancing GPCR-targeted drug discovery. Curated intelligence on GPCR drug discovery trends and developments Expert-led webinars and masterclasses

How receptor residence time — not affinity — rescued a CRF drug discovery program, and why a career in The Neurocrin team had to confront an explanation no assay had been designed to find — and then built underlying pharmacological theory, from operational models of agonism to allosteric binding equations, was designed affinity at pH 7.4 vanished entirely at the physiological vesicle pH of 5.5 — the pattern recurs: assays designed GPCR Member ResearchGate Dr. GPCR Ecosystem Unlock the Full Dr.

GPCR pharmacology, receptor signaling, and drug discovery evolved inside one of the world’s largest pharmacology and drug discovery. Serendipity Depends on Experimental Design and System Choice . understanding receptor activation in patients, but requires realistic views of effect sizes and trial design research and drug discovery.

<< Back to podcast list Strategic Partner(s) Empowering Drug Discovery for the GPCR Community with Dr GPCR Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses GPCR Podcast? Leave a Review.

Explore their innovative GPCR projects, collaborations, and contributions to cutting-edge drug discovery innovative fluorescent probes that de-risk the pre-clinical drug discovery phase. dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design GPCR Functional Assay Fluorescent GTPγS enables sensitive, non-radioactive GPCR activity assays for drug Custom Development Tailored fluorescent probes designed for unique research requirements.

ABOUT THE GUEST David Gloriam is a professor at the University of Copenhagen's Department of Drug Design design, pharmacology, and structural biology. design Data-accelerated receptor evolution: engineering GPCR function at the single residue level KEY Biased Agonism Still Needs Its Proof of Concept A drug designed around biased agonism principles received Until that pathway-level map is built, designing genuinely biased drugs remains a hypothesis in search

Targets GPCRs account for a substantial fraction of validated drug targets, yet most are drugged by Motif-directed library design — encoding ligand-binding sequences into CDR3 architecture The library The design decision is the library's main differentiator. A motif-directed library reaches targets its motifs weren't designed for. by incorporating these natural binding partners into Twist’s antibody library design.

architecture means for neurological disease and drug design. << Back to podcast list Strategic Partner within the GPCR superfamily. design can achieve: a compound that confers analgesia through G protein signaling while avoiding the drug design. 23:37 - What full-length structures in multiple states still need to deliver for drug design 25:01 -

GPCR Ecosystem We unite the GPCR Community to advance drug discovery Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools We designed the Ecosystem to support your work —no matter where you are in your GPCR journey. behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by Design Connects researchers

for plate readers, specifically designed to study internalization using time-resolved fluorescence ( View Reagents Explore Revvity’s GPCR Assay Technologies Tools designed to illuminate every step of GPCR GPCR Spotlights Revvity’s pHSense™ Reagents for Real-Time GPCR Internalization A new reagent family designed GPCR, the global nonprofit platform dedicated to advancing GPCR research and drug discovery, is proud A Tool Designed for Real Research Needs Built on more than two decades of GPCR assay innovation, pHSense

GPCR Ecosystem , a space designed to break silos, spark collaboration, and open real dialogue across Featured Appearances Aug 2020 — Featured on 17 Minutes of Science with Advancing GPCR Drug Discovery Mar 2022 — Media Partner at GPCR Targeted Drug Discovery Summit . Feb 2023 — Media Partner at GPCR Targeted Drug Discovery Summit . Community Engagement Mar 2024 — Media Partner at 3rd GPCR Targeted Drug Discovery Summit .

models and intracellular receptor targeting are reshaping drug discover << Back to podcast list Strategic The discussion also explores GPCRs beyond the cell surface — including caged ligands designed to drug Intracellular GPCRs as Drug Targets — Receptors on the nuclear and mitochondrial membranes represent an untapped pharmacological frontier, and caged ligands offer a route to drugging them selectively. Drugging GPCRs on the Nuclear Membrane GPCRs are not confined to the cell surface. Dr.